Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The partners expect to file an IND for first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet for obesity later this year.
read more
The drugmakers will combine their generics businesses and Endo's sterile injectables business and intend to eventually separate the combined unit.
read more
The Swiss-Dutch health and nutrition company has introduced a new portfolio of taste solutions specifically designed for use in pharma formulations.
read more
Proceeds will support the continued clinical development of the company's TEAD autopalmitoylation inhibitor, VT3989, with an initial focus on mesothelioma.
read more
Taro Pharmaceuticals and Lupin have received U.S. FDA approvals for generic versions of Bayer’s Xarelto (rivaroxaban) 2.5 mg tablets.
read more
Pharmacokinetic data suggested that the neflamapimod capsules used during the initial trial —
from an older batch — may have had lower bioavailability.
read more
The drugmaker will discontinue its phase 3 development program evaluating aticaprant as an add-on treatment for major depressive disorder.
read more
In a deal worth approximately $935 million, Jazz will pick up a novel first-in-class treatment for rare pediatric brain tumors with an August PDUFA date.
read more
A combination of vitamin D, omega-3 and exercise can produce a small protective effect on biological aging, according to a recent study.
read more
The FDA has expanded the approval of Odactra tablets to include the treatment of house dust mite allergies in children ages five through 11 years.
read more
An undisclosed buyer will pick up Zevra’s rare pediatric disease PRV obtained from the approval of Miplyffa for Niemann-Pick disease.
read more
The FDA has approved Mirum’s Ctexli tablets for the treatment of cerebrotendinous xanthomatosis, a rare, progressive and debilitating disease.
read more
Dr. Patrizia Cavazzoni, who retired as director of CDER in January, will head back to Pfizer.
read more
Cosette will acquire all the outstanding shares of the Australia-based women’s health and dermatology company for approximately $430 million.
read more
FibroGen has sold its China subsidiary to long-time partner, AstraZeneca, for approximately $160 million.
read more